Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

This study is for men aged 18 or older who have been recently diagnosed with prostate cancer that has spread to other parts of the body. You would need to be starting your first hormone treatment (androgen deprivation therapy) for this advanced stage of cancer.

To be included, your body's organs, like your blood, liver, and kidneys, need to be working well enough. Doctors will also check your general health and how well you can go about your daily activities. You must be willing to follow all the study's instructions, including taking medication and attending appointments.

However, some specific health conditions might mean you can't join. For example, if you have certain rare types of prostate cancer, a history of seizures, a recent stroke, or serious heart problems within the last three months, the study might not be suitable for you.

If you join this study, you would first fill out some health questionnaires. Then, you would be randomly assigned to receive either enzalutamide or a standard hormone treatment (either medication or surgery). You would start your assigned treatment within 7 days of being accepted into the study. This involves taking medication, or having surgery as appropriate. You'll have regular hospital visits for check-ups, blood tests, and scans to see how your body is responding to the treatment. These visits will continue for a certain period, and even after you stop the main treatment, there will be follow-up appointments to track your long-term health. The total duration of your participation, including follow-up, could be several years.